Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dengyin Naotong for mild cognitive impairment in cerebral small vessel disease
ChiCTR2100045831Phase 4Recruiting
- Sponsor
- Shandong Second Provincial General Hospital
- Start
- May 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Dengyin Naotong in Mild Cognitive Impairment (MCI) and Cerebral Small Vessel Disease (CSVD) (2 arms), sponsored by Shandong Second Provincial General Hospital. Primary endpoint: Montreal Cognitive Assessment Scale. Started May 2021; status: recruiting.
02
Drugs
Dengyin Naotong
03
Conditions
Mild Cognitive Impairment (MCI)Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on ChiCTR2100045831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045831.